A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(20 sites)

United States

Clinical Research Institute of Arizona, Sun City West, Arizona

Scripps Health - Whittier Diabetes Institute, La Jolla, California

UF Health Jackson, Jacksonville, Florida

East Coast Institute of Research LLC, Jacksonville, Florida

East Coast Institute of Research LLC, Lake City, Florida

Floridian Clinical Research, Miami Lakes, Florida

Louisville Metabolic and Atherosclerosis Research Center (L-MARC), Louisville, Kentucky

MD Medical Research, Oxon Hill, Maryland

Jefferson City Medical Group, Jefferson City, Missouri

Montana Medical Research, Missoula, Montana

Inspira Health - Internal Medicine Associates, Bridgeton, New Jersey

Central New York Clinical Research, Manlius, New York

Velocity Clinical Research, Durham, North Carolina

Floridian Clinical Research, Greensboro, North Carolina

Centricity Research dba Lucas Research, Morehead City, North Carolina

Summit Research Group, Munroe Falls, Ohio

Juno Research LLC - Medical Center, Houston, Texas

Clinical Trials of Texas dba Flourish Research, San Antonio, Texas

Burke Internal Medicine, Burke, Virginia

Burke International Medicine DBA Manassas Clinical Research Center, Manassas, Virginia